ClinicalTrials.gg
RecruitingNCT07441681Updated Oct 27, 2026

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

A Phase 3 interventional study of Biospecimen Collection and Carboplatin in Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma and Locally Advanced Oral Cavity Squamous Cell Carcinoma, sponsored by NRG Oncology. Recruiting at 150 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by NRG Oncology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 27, 2026Eligibility revisedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
454
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
6th of 84
454 · median 46
Started
2026
with 1 other
Phase 3
16 of 86
4 open now
Primary completion
2035-11
later than 18 of 18 live
Registered
86th of 86
by date

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 6th largest by planned enrollment of the 84 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 18 of the 18 other live ones, and was the 86th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Intensity modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. It is not yet know if cetuximab or chemotherapy, with intensity modulated radiation therapy works best for the treatment of patients with advanced head and neck cancer who are unable to receive cisplatin.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine whether radiation therapy (RT) and concurrent carboplatin and paclitaxel (RT + carboplatin and paclitaxel [CP]) improves progression-free survival (PFS) compared to RT with concurrent cetuximab (RT + cetuximab [Cetux]) in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) between RT+CP versus (vs.) RT + Cetux. II. To compare PFS and OS by study arm within p16-negative and p16-positive subgroups.

III. To compare safety and toxicity of RT+CP vs. RT + Cetux. IV. To compare patterns of failure (locoregional and distant) and competing causes of death of RT+CP vs. RT + Cetux.

V. To compare changes in diet, eating, and speech behaviors between RT+CP vs. RT + Cetux.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) 5 days per week for 35 treatments. Starting within 7 days prior to radiation, patients receive a loading dose of cetuximab intravenously (IV) and then concurrently with radiation on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT during screening, blood sample collection throughout the study, and fludeoxyglucose F-18 (FDG) PET/CT during follow-up.

ARM 2: Patients undergo IMRT 5 days per week for 35 treatments. Starting on day 1 of radiation, patients receive concurrent carboplatin IV and paclitaxel on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, or PET/CT during screening, blood sample collection throughout the study, and FDG PET/CT during follow-up.

After completion of study treatment, patients are followed up at 30 days and then 4, 6, 12, 18, 24, 30 and 36 months then annually thereafter.

03

Conditions studied

  • Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
  • Locally Advanced Laryngeal Squamous Cell Carcinoma
  • Locally Advanced Oral Cavity Squamous Cell Carcinoma
  • Locally Advanced Oropharyngeal Squamous Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have confirmed, previously untreated, unresected squamous cell carcinoma of the larynx, hypopharynx, oropharynx, or oral cavity
  • Local evaluation of p16 status is required for all oropharynx patients prior to registration
  • Local evaluation of p16 status is recommended for non-oropharynx patients prior to registration
  • Locoregionally advanced head and neck squamous cell carcinoma (HNSCC) defined as:

    • Non-oropharynx and p16-negative oropharynx cancer: American Joint Commission on Cancer (AJCC) 9th edition stage III-IVB

      • Eligible Laryngeal, Hypopharyngeal, Oral Cavity, and p16-Negative Oropharyngeal Primaries:

        • AJCC 9th Edition TNM: T3 N0 or T1-3 N1 M0; AJCC 9th Edition Stage: III
        • AJCC 9th Edition TNM: T1-3 N2 or T4a N0-N2 M0; AJCC 9th Edition Stage: IVA
        • AJCC 9th Edition TNM: T4b N0-N2 or T1-4b N3 M0; AJCC 9th Edition Stage: IVB
    • p16-positive oropharynx cancer: AJCC 9th edition stage II-III

      • Eligible p16-Positive Oropharyngeal Primaries

        • AJCC 9th Edition TNM: T3 N0-2 or T1-2 N2 M0; AJCC 9th Edition Stage: II
        • AJCC 9th Edition TNM: T4 N0-3 or T1-3 N3 M0; AJCC 9th Edition Stage: III
  • The following are required prior to registration:

    • Imaging of the head and neck with a neck CT or MRI (with contrast, unless ) or PET/CT which includes diagnostic-quality CT of the neck (with contrast, unless contraindicated)
    • Chest imaging: Chest CT (with contrast, unless contraindicated) or PET/CT
  • Age ≥ 18
  • Complete the online tool at www.nrgoncology.org prior to registration and record the (modified) Charleston Comorbidity Index (CCI), Head and Neck Cancer Intergroup (HNCIG) omega, and G-8 scores on the registration form in Oncology Patient Enrollment Network (OPEN)
  • Patients must have a contraindication to cisplatin as defined in the following bullet points:

    • Absolute or relative contraindication to cisplatin, defined as ONE OR MORE of the following prior to registration:

      • (CrCl) \< 60 mL/min by the Cockroft-Gault formula
      • Pre-existing peripheral (sensory or motor) neuropathy grade ≥ 2 (per [CTCAE] version [v] 5.0)
      • History of hearing loss, defined as either:

        • Existing need of a hearing aid OR
        • ≥ 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated OR
    • age ≥ 70 with Head and Neck Cancer Intergroup (HNCIG) omega score \< 0.80 prior to registration OR
    • Age \< 70 with ALL of the following conditions prior to registration (see Appendix II for calculation instructions):

      • HNCIG omega score \< 0.80
      • (Modified) Charlson Comorbidity Index (CCI) ≥ 1
      • G-8 score ≤ 14
  • Not pregnant and not nursing
  • Participants must be able to safely receive the radiation and drug regimens per current Food and Drug Administration (FDA)-approved package insert(s), treating investigator's discretion, and institutional guidelines
  • No prior systemic therapy for the study cancer; note that prior systemic therapy for a different cancer is allowable
  • No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • No prior surgery for the study cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
454 participants (estimated)

Study arms

  • Experimental
    Arm 1 (IMRT, cetuximab)

    Patients undergo IMRT 5 days per week for 35 treatments. Starting within 7 days prior to radiation, patients receive a loading dose of cetuximab IV and then concurrently with radiation on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, or PET/CT during screening, blood sample collection throughout the study, and FDG PET/CT during follow-up.

    Procedure: Biospecimen Collection · Biological: Cetuximab · Procedure: Computed Tomography · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Survey Administration

  • Active comparator
    Arm 2 (IMRT, carboplatin, paclitaxel)

    Patients undergo IMRT 5 days per week for 35 treatments. Starting on day 1 of radiation, patients receive concurrent carboplatin IV and paclitaxel on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan on study and blood sample collection throughout the study. Patients may undergo PET scan or MRI during screening.

    Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • BiologicalCetuximab

    Given IV

    Also known as: C 225, C-225, C225, Cetuxa, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Cetuximab-cetu, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, ENZ 124, ENZ-124, ENZ124, Erbitux, IMC-C225

  • ProcedureComputed Tomography

    Undergo FDG PET/CT and CT or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

    Also known as: IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • ProcedurePositron Emission Tomography

    Undergo PET/CT and/or FDG PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    The PFS rates for each treatment arm will be estimated in the overall sample and within each p16 subgroup using the Kaplan-Meier method. Estimates of the median PFS and 2-year PFS rates will be obtained with 90% confidence intervals. The comparison of PFS distributions between each treatment arm will be performed using a one-sided stratified log-rank test (stratified by the randomization stratification factors). As additional analysis of treatment effect, multivariable analysis will be performed using a Cox proportional hazards model, where the stratification factors, and relevant patient and tumor characteristics are included (as measured by the model's Bayesian Information Criterion \[BIC\]). Hazard ratios and their respective 90% confidence intervals will be provided.

    Time frame: From randomization until locoregional failure, distant failure, or death due to any cause, up to 8 years

Secondary outcomes

  1. Overall survival (OS)

    Will be summarized by treatment arm using standard Kaplan-Meier methods, where estimates of the median and 2-year OS will be obtained with 90% confidence intervals. The OS will be compared using a one-sided stratified log-rank test, stratified by the randomization strata.

    Time frame: From randomization until death due to any cause, up to 8 years

  2. OS by p16 status

    Assessments within p16 subgroups is to compare treatment arms within potentially clinically relevant subgroups. Within p16-negative and p16-positive subgroups, the OS will be summarized by study arm using standard Kaplan-Meier methods. The median OS and 2-year OS rates will be reported with 90% confidence intervals. Comparisons will be made using one-sided stratified log-rank tests. Multivariate Cox regression models will also be considered, where relevant covariates are selected based on the model's BIC.

    Time frame: From randomization until death due to any cause, up to 8 years

  3. PFS by p16 status

    PFS assessments within p16 subgroups is to compare treatment arms within potentially clinically relevant subgroups. Within p16-negative and p16-positive subgroups, the PFS will be summarized by study arm using standard Kaplan-Meier methods. The median PFS and 2-year PFS rates will be reported with 90% confidence intervals. Comparisons will be made using one-sided stratified log-rank tests. Multivariate Cox regression models will also be considered, where relevant covariates are selected based on the model's BIC. No adjustments will be made for multiplicity.

    Time frame: From randomization until locoregional failure, distant failure, or death due to any cause, up to 8 years

  4. Incidence of adverse events

    Adverse event grades will be assessed by Common Terminology Criteria for Adverse Events version 5.0. The overall (highest grade) adverse events will be summarized by treatment arm using frequencies and relative frequencies.

    Time frame: Up to 24 months from end of radiation therapy (RT)

  5. Incidence of patient reported incidence of adverse events

    Patient responses will be summarized by treatment arm and time point using frequencies and relative frequencies.

    Time frame: Up to 12 months from end of RT

  6. Time to locoregional failure

    Will compare patterns of failure and competing causes of death between treatment arms. The number and type of failures will be summarized by treatment arm using frequencies and relative frequencies. The time to failure will be summarized by treatment arm using the cumulative incidence method, where estimates of the 2-year failure rates will be obtained with 90% confidence intervals. Comparisons between treatment arms will be made using the stratified Gray's test.

    Time frame: From randomization until first evidence of local, regional disease progression or recurrence, or death from study cancer, up to 8 years

  7. Time to distant failure

    Will compare patterns of failure and competing causes of death between treatment arms. The number and type of failures will be summarized by treatment arm using frequencies and relative frequencies. The time to failure will be summarized by treatment arm using the cumulative incidence method, where estimates of the 2-year failure rates will be obtained with 90% confidence intervals. Comparisons between treatment arms will be made using the stratified Gray's test.

    Time frame: From randomization until first evidence of distant metastasis, up to 8 years

  8. Time to competing mortality

    Will compare patterns of failure and competing causes of death between treatment arms. The number and type of failures will be summarized by treatment arm using frequencies and relative frequencies. The time to failure will be summarized by treatment arm using the cumulative incidence method, where estimates of the 2-year failure rates will be obtained with 90% confidence intervals. Comparisons between treatment arms will be made using the stratified Gray's test.

    Time frame: From randomization until death due to other or unknown causes, up to 8 years

  9. Longitudinal eating/speech profiles

    Assessed via the Performance Status Scale for Head and Neck Cancer. The mean score change (relative to end of radiation treatment) for each of these subscales between arms will be compared at 12 months post-RT using a two-sample independent t-test with a two-sided significance level of 0.05. A Wilcoxon test will be used if normality assumption does not hold. Temporal trends and differences between arms at other time points will be assessed using mixed models with the following covariates: time, treatment arm and its interaction.

    Time frame: At baseline, end of treatment, 4, 6 and 12 months from end of RT

Other outcomes

  1. Primary outcome treatment effect by sex

    Estimates of treatment effect and the corresponding 95% confidence intervals will be provided.

    Time frame: Up to 8 years

  2. Primary treatment outcome by race

    Estimates of treatment effect and the corresponding 95% confidence intervals will be provided.

    Time frame: Up to 8 years

  3. Primary treatment outcome by ethnicity

    Estimates of treatment effect and the corresponding 95% confidence intervals will be provided.

    Time frame: Up to 8 years

07

Study locations

150 of 150 sites recruiting

Showing the first 100 of 150 sites. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2035, 111 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 111 months is above that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Nov 30, 2035
CompletionEst.
Nov 30, 2040
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
87 sites added
Show 87 added (87 United States)
  • University of Alabama at Birmingham Cancer Center · Birmingham, United States
  • Kaiser Permanente-Anaheim · Anaheim, United States
  • Kaiser Permanente-Baldwin Park · Baldwin Park, United States
  • Kaiser Permanente-Bellflower · Bellflower, United States
  • Kaiser Permanente-Fontana · Fontana, United States
  • Kaiser Permanente South Bay · Harbor City, United States
  • Kaiser Permanente-Irvine · Irvine, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, United States
  • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United States
  • Kaiser Permanente West Los Angeles · Los Angeles, United States
  • Kaiser Permanente-Ontario · Ontario, United States
  • Stanford Cancer Institute Palo Alto · Palo Alto, United States
  • Kaiser Permanente - Panorama City · Panorama City, United States
  • Kaiser Permanente-Riverside · Riverside, United States
  • Kaiser Permanente-San Diego Zion · San Diego, United States
  • Stanford Cancer Center South Bay · San Jose, United States
  • Kaiser Permanente-San Marcos · San Marcos, United States
  • Kaiser Permanente-Woodland Hills · Woodland Hills, United States
  • Emory Proton Therapy Center · Atlanta, United States
  • Emory University Hospital Midtown · Atlanta, United States
  • Carle at The Riverfront · Danville, United States
  • Northwestern Medicine Cancer Center Kishwaukee · DeKalb, United States
  • Carle Physician Group-Effingham · Effingham, United States
  • Northwestern Medicine Cancer Center Delnor · Geneva, United States
  • Carle Physician Group-Mattoon/Charleston · Mattoon, United States
  • Northwestern Medicine Oak Brook · Oak Brook, United States
  • UW Health Carbone Cancer Center Rockford · Rockford, United States
  • Carle Cancer Center · Urbana, United States
  • Northwestern Medicine Cancer Center Warrenville · Warrenville, United States
  • Mary Greeley Medical Center · Ames, United States
  • …and 57 more on the registry record
Oct 27, 2026
Eligibility
7 criteria edited, 1 added, 6 removed
What changed in the criteria
  • EditedNon-oropharynx and p16-negative oropharynx cancer: American Joint Commission on Cancer (AJCC) 8th9th edition stage III-IVB
  • EditedEligible Laryngeal, Hypopharyngeal, Oral Cavity, and p16-Negative Oropharyngeal Primaries:
  • EditedAJCC 8th9th Edition TNM: T3 N0 or T1-4b N1-3 N1 M0; AJCC 8th9th Edition Stage: III-IVB
  • AddedAJCC 9th Edition TNM: T1-3 N2 or T4a N0-N2 M0; AJCC 9th Edition Stage: IVA
  • EditedAJCC 8th9th Edition TNM: T3T4b N0-N2 or T1-4b N0N3 M0; AJCC 8th9th Edition Stage: III-IVB
  • Editedp16-positive oropharynx cancer: AJCC 8th9th edition stage II-III and selected stage I-II based on smoking status in pack-years
  • RemovedAJCC 8th Edition TNM: T1-2 N1 M0 AJCC 8th Edition Stage: I Pack-Years: > 10
  • EditedAJCC 8th9th Edition TNM: T3 N0-2 or T1-2 N2 M0; AJCC 8th9th Edition Stage: II Pack-Years: any
  • RemovedAJCC 8th Edition TNM: T3 N0-1 M0 AJCC 8th Edition Stage: II Pack-Years: > 10
  • RemovedAJCC 8th Edition TNM: T3 N2 M0 AJCC 8th Edition Stage: II Pack-Years: any
  • EditedAJCC 8th9th Edition TNM: T4 N0-3 or T1-3 N3 M0; AJCC 8th9th Edition Stage: III Pack-Years: any
  • RemovedAJCC 8th Edition TNM: T4 N0-3 M0 AJCC 8th Edition Stage: III Pack-Years: any
  • RemovedNote: Number of pack-years = [Frequency of smoking (number of cigarettes per day) × duration of cigarette smoking (years)] / 20
  • RemovedNote: Cigar and pipe tobacco consumption is not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is also no clear scientific evidence regarding the role of chewing tobacco-containing products in oropharyngeal cancer, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators should not count use of non-cigarette tobacco products in the pack-years calculation
Oct 27, 2026
Title
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    87 sites added
    Show 87 added (87 United States)
    • University of Alabama at Birmingham Cancer Center · Birmingham, United States
    • Kaiser Permanente-Anaheim · Anaheim, United States
    • Kaiser Permanente-Baldwin Park · Baldwin Park, United States
    • Kaiser Permanente-Bellflower · Bellflower, United States
    • Kaiser Permanente-Fontana · Fontana, United States
    • Kaiser Permanente South Bay · Harbor City, United States
    • Kaiser Permanente-Irvine · Irvine, United States
    • The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, United States
    • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United States
    • Kaiser Permanente West Los Angeles · Los Angeles, United States
    • Kaiser Permanente-Ontario · Ontario, United States
    • Stanford Cancer Institute Palo Alto · Palo Alto, United States
    • Kaiser Permanente - Panorama City · Panorama City, United States
    • Kaiser Permanente-Riverside · Riverside, United States
    • Kaiser Permanente-San Diego Zion · San Diego, United States
    • Stanford Cancer Center South Bay · San Jose, United States
    • Kaiser Permanente-San Marcos · San Marcos, United States
    • Kaiser Permanente-Woodland Hills · Woodland Hills, United States
    • Emory Proton Therapy Center · Atlanta, United States
    • Emory University Hospital Midtown · Atlanta, United States
    • Carle at The Riverfront · Danville, United States
    • Northwestern Medicine Cancer Center Kishwaukee · DeKalb, United States
    • Carle Physician Group-Effingham · Effingham, United States
    • Northwestern Medicine Cancer Center Delnor · Geneva, United States
    • Carle Physician Group-Mattoon/Charleston · Mattoon, United States
    • Northwestern Medicine Oak Brook · Oak Brook, United States
    • UW Health Carbone Cancer Center Rockford · Rockford, United States
    • Carle Cancer Center · Urbana, United States
    • Northwestern Medicine Cancer Center Warrenville · Warrenville, United States
    • Mary Greeley Medical Center · Ames, United States
    • …and 57 more on the registry record
    Eligibility 7 criteria edited, 1 added, 6 removed
    What changed in the criteria
    • EditedNon-oropharynx and p16-negative oropharynx cancer: American Joint Commission on Cancer (AJCC) 8th9th edition stage III-IVB
    • EditedEligible Laryngeal, Hypopharyngeal, Oral Cavity, and p16-Negative Oropharyngeal Primaries:
    • EditedAJCC 8th9th Edition TNM: T3 N0 or T1-4b N1-3 N1 M0; AJCC 8th9th Edition Stage: III-IVB
    • AddedAJCC 9th Edition TNM: T1-3 N2 or T4a N0-N2 M0; AJCC 9th Edition Stage: IVA
    • EditedAJCC 8th9th Edition TNM: T3T4b N0-N2 or T1-4b N0N3 M0; AJCC 8th9th Edition Stage: III-IVB
    • Editedp16-positive oropharynx cancer: AJCC 8th9th edition stage II-III and selected stage I-II based on smoking status in pack-years
    • RemovedAJCC 8th Edition TNM: T1-2 N1 M0 AJCC 8th Edition Stage: I Pack-Years: > 10
    • EditedAJCC 8th9th Edition TNM: T3 N0-2 or T1-2 N2 M0; AJCC 8th9th Edition Stage: II Pack-Years: any
    • RemovedAJCC 8th Edition TNM: T3 N0-1 M0 AJCC 8th Edition Stage: II Pack-Years: > 10
    • RemovedAJCC 8th Edition TNM: T3 N2 M0 AJCC 8th Edition Stage: II Pack-Years: any
    • EditedAJCC 8th9th Edition TNM: T4 N0-3 or T1-3 N3 M0; AJCC 8th9th Edition Stage: III Pack-Years: any
    • RemovedAJCC 8th Edition TNM: T4 N0-3 M0 AJCC 8th Edition Stage: III Pack-Years: any
    • RemovedNote: Number of pack-years = [Frequency of smoking (number of cigarettes per day) × duration of cigarette smoking (years)] / 20
    • RemovedNote: Cigar and pipe tobacco consumption is not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is also no clear scientific evidence regarding the role of chewing tobacco-containing products in oropharyngeal cancer, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators should not count use of non-cigarette tobacco products in the pack-years calculation
    Title Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
    + 6 other changes: index terms, verification date, description, conditions, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07441681
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Jul 31, 2026
Primary completion
Nov 30, 2035 (estimated)
Completion
Nov 30, 2040 (estimated)
Last update
Oct 27, 2026

Study contacts

Loren K Mell
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion